Though I got into this stock because of B, this last year I have increasingly harbored the suspicion that Leo and company are thinking that the road to bigtime status and profits is through the multiple treatment applications of K as a single or as an adjuvant treatment. Lots of disparate clues could point to this. And the Italians may agree. We can hope.